Papillary thyroid carcinoma
Conditions
Interventions
experimental group:thyroid tablets
Sponsors
The First People's Hospital of Hangzhou Affiliated to Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. Patients with differentiated thyroid cancer (DTC) diagnosed by pathological examination and belonging to ATA low-risk group with TSH inhibition target value below 0.5; 3. Thyroid cancer surgery, lymph node dissection in the central area of the affected side or modified neck lymph node dissection, etc; 4. Patients voluntarily participated and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with pathological diagnosis of Schutter cell carcinoma or undifferentiated thyroid carcinoma, including medullary thyroid carcinoma (MTC) or undifferentiated thyroid carcinoma (anaplastic thyroid carcinoma) (ATC); 2. Patients with other thyroid diseases, such as hyperthyroidism or toxic nodular goiter; 3. Known gastrointestinal diseases (gastrointestinal malabsorption, such as gastritis related to Helicobacter pylori infection, atrophic gastritis, celiac disease, lactose intolerance, etc., or a history of gastric bypass surgery); 4. Patients with contraindications to levothyroxine sodium tablets and thyroid tablets; 5. Serious dysfunction of heart, kidney, liver, respiratory tract, pituitary and other important organs or history of major diseases (such as serious cardiovascular damage, arrhythmia, etc.); 6. Suffering from serious mental illness or having a history of mental disorders; 7. Pregnant or lactating patients; 8. Suffering from chronic diseases such as autoimmune diseases; 9. Drugs that interfere with the absorption or metabolism of levothyroxine sodium tablets or thyroid tablets are currently being used (e.g., estrogen and testosterone, iodine, propranolol, amiodarone, dopamine agonists or antagonists, somatostatin analogues, steroids, phenytoin sodium, proton pump inhibitors, etc.); 10. Left thyroxine sodium tablets or thyroid tablets or T3 preparations have been used before.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total clinical response rate at week 24; | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients whose serum TSH levels reached the target, mean TSH and changes from baseline in the two groups;Thyroid function evaluation (FT3, FT4 levels) of patients in two groups;Changes of clinical symptom scores in the two groups from baseline; | — |
Countries
China
Contacts
Public ContactPeng You
The First People's Hospital of Hangzhou Affiliated to Zhejiang University School of Medicine
Outcome results
None listed